Search
Triamcinolone
go.drugbank.com/drugs/DB00620ApprovedInvestigationalVet approved[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.
Mixtures: KRIM PI KANG SHUANG, P-Care K40Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersToripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalOne mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsLevonorgestrel
go.drugbank.com/drugs/DB00367ApprovedInvestigational[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD.
Synonyms: d(-)-NorgestrelCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigationalDostarlimab is an IgG<sub>4</sub> humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). … [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsAtropine
go.drugbank.com/drugs/DB00572ApprovedInvestigationalVet approvedAtropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. … [A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods.
Mixtures: PB Hyos, Re-PB HyosCategories: P-glycoprotein substratesAlbuterol
go.drugbank.com/drugs/DB01001ApprovedInvestigationalVet approvedSalbutamol (Albuterol [USAN]) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity fo...
Mixtures: AXOL DUOCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsCetirizine
go.drugbank.com/drugs/DB00341ApprovedInvestigationalCetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal
Mixtures: Zyrtec-D, Cetiri DCategories: P-glycoprotein inhibitors, P-glycoprotein substratesDoxycycline
go.drugbank.com/drugs/DB00254ApprovedInvestigationalVet approvedDoxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generatio...
International brands: Nu-DoxycyclineCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsDoconexent
go.drugbank.com/drugs/DB03756ApprovedInvestigationalIt is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin, and retina thus plays an important role in their development and function. … It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae.
Mixtures: Triveen-Duo DHA, Se-Tan DHACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalIt is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates